Notch3 Pathway Alterations in Ovarian Cancer

Wei Hu1, Tao Liu1, Cristina Ivan1,8, Yunjie Sun1, Jie Huang1, Lingewoda S. Mangala1,8, Takahito Miyake1, Heather J. Dalton1, Sunila Pradeep1, Rajesh Rupaimoole1, Rebecca A. Previs1, Hee Dong Han1, Justin Bottsforder-Miller1, Behrouz Zand1, Yu Kang1, Chad V. Pecot1, Alpa M. Nick1, Sherry Y. Wu1, Ju-Seog Lee2, Vasudha Sehgal2, Prahlad Ram2, Jinsong Liu3, Susan L. Tucker5, Gabriel Lopez-Berestein4,6,8, Keith A. Baggerly5, Robert L. Coleman1, and Anil K. Sood1,6,8

Abstract

The Notch pathway plays an important role in the growth of high-grade serous ovarian (HGS-OvCa) and other cancers, but its clinical and biologic mechanisms are not well understood. Here, we found that the Notch pathway alterations are prevalent and significantly related to poor clinical outcome in patients with ovarian cancer. Particularly, Notch3 alterations, including amplification and upregulation, were highly associated with poor patient survival. Targeting Notch3 inhibited ovarian cancer growth and induced apoptosis. Importantly, we found that dynamin-mediated endocytosis was required for selectively activating Jagged-1-mediated Notch3 signaling. Cleaved Notch3 expression was the critical determinant of response to Notch-targeted therapy. Collectively, these data identify previously unknown mechanisms underlying Notch3 signaling and identify new, biomarker-driven approaches for therapy. Cancer Res; 74(12); 3282–93. ©2014 AACR.

Introduction

Notch signaling has been implicated in tumor angiogenesis processes such as vessel maturation; pericyte recruitment; branching; and cell differentiation, proliferation, and survival. In mammalian cells, this pathway comprises five transmembrane Notch ligands [Jagged-1, Jagged-2, Delta-like ligand (DLL) 1, DLL3, and DLL4] and four Notch receptors (Notch1–4). Mature Notch receptors are assembled as heterodimeric proteins, with each dimer comprised of a large extracellular ligand-binding domain, a single-pass transmembrane domain, and a smaller cytoplasmic subunit (Notch intracellular domain, NICD; ref. 1). The activation of Notch signaling requires endocytosis and trafficking of both notch receptor and ligand. Upon ligand–receptor binding, it leads to cleavage of the Notch receptor via intramembrane proteolysis by the gamma-secretase complex (including presenilin, nicastin, APH1 and PEN2) and results in consequent release of NICD. The NICD fragment then enters the nucleus and interacts with nuclear DNA-binding factor, CSL (suppressor of hailess/LAG-1, RBPIK) to regulate transcription of the basic helix-loop-helix genes, hairy and enhancer-of-split genes, and Notch target genes (2, 3).

However, the biologic role of Notch pathway alterations in cancer growth and the clinical effects of these alterations are not well understood (4–7). In the present study, we performed an integrated and systematic analysis of the clinical relevance of the Notch pathway in high-grade serous ovarian cancer (HGS-OvCa) and identified novel mechanisms of Notch3 activation.

Materials and Methods

The Cancer Genome Atlas clinical analysis

Access to The Cancer Genome Atlas (TCGA) database was approved by the National Cancer Institute. The University of Texas MD Anderson Cancer Center approved a waiver for performing our survival analysis with deidentified data. Demographic characteristics and clinical data of patients with HGS-OvCa (histopathologic information, treatment, and outcome parameters) were downloaded from the data portal for TCGA (http://tcga.cancer.gov; Supplementary Table S1). The survival analysis output for the 316 study patients and complete information [overall survival (OS) and progression-free survival duration, expression, mutation, copy number] were downloaded from the cBio Cancer Portal for Genomics (http://www.cbioportal.org/public-portal/). Also, complete survival and gene expression information for our OS and progression-free survival analysis of 453 and 373 patients with HGS-OvCa, respectively, were downloaded from TCGA. The mean age of the patients at diagnosis and...
tumor stage (as defined by the International Federation of Gynecology and Obstetrics), tumor grade, and surgical outcomes (residual tumor size) reflected those in individuals typically diagnosed with HGS-OvCa. The patients' tumor specimens had been resected before systemic treatment. All the patients had received a platinum agent, and 94% had received a taxane. The platforms used were described in the TCGA article (4).

Copy-number alterations were analyzed using the Human Genome CGH Microarrays (244 k, 415 K, or 1 M platforms; Agilent Technologies), and focally amplified regions were identified using a modified method (4). Level 3 gene expression data were generated using three platforms: Agilent Technologies, GeneChip Human Exon ST Array (Affymetrix), and GeneChip Human Genome U133A 2.0 Array (Affymetrix). We downloaded the Notch2–4 mutation data from TCGA (Supplementary Table S1); these data were generated using the Genome Analyzer Ix platform (Illumina) and the ABI SOLiD 3 System (Life Technologies/Applied Biosystems).

Cell lines and cell culture

Ovarian cancer cell lines (OVCAR3, OVCAR5, OVCAR420, SKOV3, SKOV3 TR, HeyA8, HeyA8 MDR, A2780, IGROV1, A2774, and HI180) and the uterine cancer cell line (Ishikawa) were obtained from the MD Anderson Characterized Cell Line Core Facility (Houston, Texas), which supplies authenticated cell lines. The cell lines were routinely tested to confirm the absence of mycoplasma, and all experiments were performed with cell lines at 60% to 80% confluence.

OVCAR420, OVCAR3, SKOV3, SKOV3 TR, HeyA8, HeyA8 MDR, A2780, and IGROV1 cells were maintained and propagated in RPMI1640 medium supplemented with 10% to 15% FBS and 0.1% gentamicin sulfate (Gemini Bio-Products). The medium used for the HeyA8 MDR and SKOV3 TR cells contained 100 mM docetaxel. OVCAR5 cells were maintained and propagated in Dulbecco’s Modified Eagle Medium/high-glucose medium supplemented with 15% FBS and 0.1% gentamicin sulfate. HI1801 and A2774 cell cultures were maintained in 10% Modified Eagle Medium.

Reagents and antibodies

Gamma-secretase inhibitor (GSI) was provided by Pfizer (New York, New York). Paclitaxel was purchased from the MD Anderson pharmacy. Notch3, Jagged-1, RPS6KB1, dynamin (DNM1)–3, control siRNAs, and dynasore were purchased from Sigma-Aldrich. Primers included PSEN1, APH1A, NCSTN, APH1B, PSENEN, RPS6KB1, DNM1–3, and 18s were also purchased from Sigma-Aldrich. Antibodies used in this study included Jagged-1, Jagged-2, DLL1, DLL4, P70S6K (RPS6KB1), Notch1–4, and cleaved Notches and were obtained from Cell Signaling Technology. Anti-DLL3 antibody was obtained from Abcam. β-Actin was purchased from Sigma-Aldrich. CD31 was purchased from BD Biosciences. Anti-Ki67 antibody was purchased from Neomarkers. Antibody against cleaved caspase-3 was purchased from Cell Signaling Technology, Horseradish peroxidase (HRP)–conjugated rat anti-mouse IgG2a was purchased from Harlan Bioproducts for Science.

Western blot analysis

Western blot analysis was performed to detect expression of Notch family members (Jagged-1, Jagged-2, DLL1, DLL3, DLL4, Notch1–4, and cleaved Notch (NICDs)) in a panel of ovarian cancer cells. Cells were lysed with RIPA lysis buffer (50 mMol/L Tris-cl pH 7.4, 150 mMol/L NaCl, 1% NP40, 0.25% Na-deoxycholate, 1 mMol/L PMSF (phenylmethysulfonylfluoride), 1× Roche complete mini protease inhibitor cocktail) and centrifuged for 15 minutes at 4°C. Protein concentrations were then measured using a Bio-Rad Protein Assay Kit (Hercules, California). After loading the protein (25 μg/well), we separated bands on an 8% to 10% gel using sodium dodecyl sulfate polyacrylamide gel electrophoresis. Bands were then transferred to nitrocellulose membrane, blocked with 5% milk for 1 hour at room temperature, and incubated with primary antibodies against Notch1–4, Jagged-1, Jagged-2, and DLL4 (1:1,000 dilution) and DLL3 (1:2,000 dilution) overnight at 4°C. The samples were incubated with HRP-conjugated anti-mouse or anti-rabbit antibodies (GE Healthcare) for 1 hour at room temperature. Blots were developed using an enhanced Chemiluminescence Detection Kit (Pierce Biotechnology, Rockford, Illinois). Actin was used as a loading control, and all experiments were performed in duplicate. Densitometry was performed using the ImageJ software program to interpret differences in Western blot analysis results.

RT-PCR

Relative expression of the gamma-secretase complex (PSEN1, NCSTN, APH1A, APH1B, and PSENEN) were detected using qRT-PCR. Dynamin expression was detected using RT-PCR. Each RT-PCR was carried out with 500 ng of total RNA isolated from treated ovarian cancer cells using an RNeasy Mini Kit (Qiagen). Quantitative RT-PCR was performed using an ABI 7500 Sequence Detection System (Applied Biosystems) with a SensiMix SYBR Low-ROX Kit (Bioline USA). Relative quantification of gene expression was performed using the 2−ΔΔCt method. The primer sequences are listed in Supplementary Table S2.

In vitro siRNA transfection

All cell lines were transfected with Lipofectamine 2000 reagent (Invitrogen) using either control or target siRNAs (Sigma-Aldrich) as specified in Supplementary Table S2 according to the manufacturer’s protocol. Cells were plated in a 6-well plate 24 hours before incubation. For 1-well transfection, we added 2 μg of target siRNA (1 μg/μL) and 6 μL of Lipofectamine 2,000 to 100 μL of serum-free medium, and the mixture was incubated for 30 minutes at room temperature. During transfection, we washed the 6-well plates once with 2 mL of PBS and then added 100 μL of the mixture along with 1 mL of serum-free medium to the plates. After 4 to 6 hours of transfection, the medium was replaced with a medium containing FBS.

Apoptosis, cell cycle, and anoikis assays

Apoptosis in the ovarian cancer cells was evaluated using an Annexin V Apoptosis Detection Kit (BD Biosciences). Cells were incubated in trypsin-EDTA, and cell pellets were
suspended in 1 mL of 1× Annexin V binding buffer. We incubated 100 µL of each cell suspension with 5 µL of Annexin V and 5 µL of 7-aminoactinomycin D at room temperature (25°C) in the dark for 30 minutes. Following this incubation, 400 µL of 1× binding buffer was added to each tube, and specimens were analyzed using an XL 4-color flow cytometer. Each experiment was repeated three times.

For cell-cycle analysis, we synchronized the treated cells by maintaining them in serum-free media for 24 hours. The cells were then trypsinized, washed with PBS, and fixed in 70% cold ethanol overnight at 4°C. Cells were then centrifuged at 1,200 rpm for 10 minutes at 4°C. After washing with PBS, cells were suspended in propidium iodide (Roche Diagnostics) at 50 µg/mL and RNase A (Qiagen) at 100 µg/mL and incubated in the dark at room temperature. We then determined the cell-cycle status using fluorescence-activated cell sorting.

For anoikis analysis, 2.0 × 10^5 ovarian cancer cells were seeded on a 6-well plate. Twenty-four hours later, cells were transfected with siRNA. After 24 hours of transfection, 2.5 × 10^5 cells were lifted and plated on a 6-well poly(2-hydroxyethyl methacrylate)-treated plate in serum-free Mito-PLUS medium and incubated for 72 hours at 37°C in a 5% carbon dioxide atmosphere. After incubation, detached and suspended cells were harvested in RPMI1640 medium and centrifuged at 500 × g for 10 minutes. Pellets were washed with PBS and fixed with ice-cold 75% (v/v) ethanol overnight at 4°C. After fixation, cells were washed with PBS and stained with 500 µL of a propidium iodide solution (50 mg/mL in PBS) containing 25 µg/mL RNase A. Cells were incubated at 37°C for 30 minutes and analyzed using fluorescence-activated cell sorting.

**Cytotoxicity assays**

Ovarian cancer cells were plated in a 96-well plate and cultured overnight. Cells were then exposed to 0.25, 0.5, 1, 2, 4, 6, 8, or 10 µmol/L of GSI for 72 hours. Control cells were treated with a vehicle at equal concentrations. To assess cell viability, we added 50 µL of 0.15% MTT (Sigma-Aldrich) to each well and incubated the well-plate for 2 hours at 37°C. The medium containing MTT was then removed, and 100 µL of dimethyl sulfoxide (Sigma-Aldrich) was added to each well. Cells were then incubated at room temperature for 10 minutes. The absorbance was read at 570 nm using a 96-well Synergy HT multi-mode microplate reader (Ceres UV 900 C; BioTek). Cell viability was defined as the percentage of viable cells in the treatment group relative to viable cells in the control group. The experiments were repeated separately at least three times.

**Microarray analysis of Notch3 downstream genes**

We analyzed the silencing of Notch3 with the Illumina cDNA microarray platform as described previously (8). Briefly, Notch3 in OVCAR3 cells was silenced in vitro using Notch3 siRNAs, and Notch3 silencing was confirmed via Western blot analysis. For microarray hybridization, total RNA was extracted from ovarian cancer cells transfected with control siRNA or human Notch3 siRNA using a mirVana RNA isolation labeling kit (Ambion). We used 500 ng of total RNA to label and hybridize the cells according to Illumina's protocols. After we scanned bead chips (Sentrix HumanHT-12 v3, Illumina) using an Illumina BeadArray reader, we normalized the microarray data using the quantile normalization method with the Linear Models for Microarray Data software program in the R language (Denton; ref. 9). The level of expression of each gene was transformed into a log2 base before additional analysis was performed. Genes that were differentially expressed in control and Notch3-silenced cells were identified using a random-variation t test; gene expression differences were considered statistically significant if their P values were less than 0.001. A stringent significance threshold was used to limit the number of false-positive findings.

In addition, cluster analysis was performed using the Cluster and TreeView software programs (10). The NetWalker software program was used for gene network analysis (11).

**In vivo mouse models**

Female athymic nude mice (NCr-nu) were purchased from the Animal Production Area of the Frederick National Laboratory for Cancer Research. The animals were kept under specific pathogen-free conditions in facilities approved by the Association for Assessment and Accreditation of Laboratory Animal Care International and in agreement with current regulations and standards of the United States Department of Health and Human Services, the United States Department of Agriculture, and the NIH. Mice used in these experiments were 8- to 12-week-old.

To generate tumors in the mice, we trypsinized subconfluent cultures of OVCAR5, A2780, and SKOV3 cells, mixed the cells with a medium containing 10% FBS, centrifuged the mixture at 1,000 rpm for 5 minutes, and washed the cells in PBS. Mice were then injected intraperitoneally with 1 × 10^7 OVCAR5, A2780, or SKOV3 cells. In the OVCAR5 and A2780 models, mice were randomized into four treatment groups of 10 mice each: control siRNA, control siRNA with paclitaxel, Notch3 siRNA, and Notch3 siRNA with paclitaxel. In the SKOV3 model, mice were randomized into two treatment groups: control siRNA and Notch3 siRNA. Treatments were initiated 8 days after tumor cell injection. Control and Notch3 siRNA were conjugated with chitosan (CH; ref. 8), which we injected into the tail vein twice weekly (150 µg/kg per mouse). Paclitaxel was administered intraperitoneally once weekly (4 mg/kg/mouse). Mice were monitored daily and weighed weekly. All of the mice were subjected to necropsy when the control mice became moribund, which was approximately 28 days after A2780 cell injection, 35 days after OVCAR5 cell injection, and 38 days after SKOV3 cell injection. Each mouse’s total body weight and the location, weight, and number of tumors were recorded. Tumor specimens processed for further analysis were either preserved in optimum cutting temperature medium (Miles Laboratories for frozen sectioning) or fixed in formalin (paraffin embedment).

To further validate target modulation (cleaved Notch3, Hes1, and RPS6KB1) in the tumor tissues obtained from the in vivo A2780 model, ovarian cancer cells were injected intraperitoneally into the mice. Three weeks later, the mice were randomly allocated to two treatment groups (n = 5/group): (i) control; (ii) dynasore (60 mg/kg i.p. for two treatments,
72 hours apart). Tumor tissues were collected for Western blot analysis.

**Immunohistochemical staining**

Paraffin-embedded orthotopic tumor specimens were used in immunohistochemical staining to detect cell proliferation (with Ki67), apoptosis (with cleaved caspase-3), and Notch3 expression. Tumor sections were deparaffinized, rehydrated, and transferred to PBS. After retrieving the antigens with citrate buffer (pH 6.0), we blocked the sections with 3% hydrogen peroxide in methanol and protein blocker at room temperature. The sections were then incubated with a monoclonal mouse anti-Ki67 antibody (1:200; Neomarkers), anti-cleaved caspase-3 antibody (1:100; Biocare Medical) overnight at 4°C. After being washed with PBS, the sections were incubated with HRP-conjugated rat anti-mouse IgG2a (1:100; Harlan Bioproducts for Science).

For CD31 detection, frozen sections were fixed in cold acetone for 15 minutes, washed with PBS, blocked with protein blocker (4% fish gel), and then incubated with rat monoclonal anti-mouse CD31 (1:800; PharMingen) overnight at 4°C. They were then washed with PBS and incubated with HRP-conjugated goat anti-rat IgG (1:200; Jackson ImmunoResearch Laboratories) for 1 hour. Reactive tissues were visualized using staining with 3,3′-diaminobenzidine (Research Genetics) and followed by counterstaining with Gill hematoxylin (BioGenex Laboratories).

To quantify Ki67, cleaved caspase-3, and Notch3, the percentage of positive cells was determined in five random 0.159-mm² fields at ×200 magnification. To quantify microvessel density (MVD) for each sample, the microvessels within five randomly selected 0.159-mm² fields were counted at ×200 magnification. A single microvessel was defined as a discrete cluster for CD31 positivity.

**Statistical analysis**

The Kaplan–Meier method was used to generate time-to-progression and survival curves. The statistical analysis was performed with the R statistical computing language (version 2.11.0; http://www.r-project.org/), and statistical significance was set at 0.05. For analysis of categorical data (tumor stage, tumor grade, and residual tumor size), the Fisher exact test was used to calculate P values. For in vivo data analysis, differences in continuous variables (mean body weight, tumor weight, tumor–cell proliferation, and apoptosis) were analyzed using the Mann–Whitney rank-sum test.

**Results**

**Clinical significance of alterations of the core Notch and related genes**

To determine the clinical relevance of alterations of the core Notch and related genes, including Notch ligands (Jagged-1, Jagged-2, DLL1, DLL3, and DLL4), Notch receptors (Notch1–4), and Notch-interacting genes (SNW1, CNTN1), we first examined the effect of these alterations on survival duration in 316 patients with HGS-OvCa from the TCGA dataset. We found that Notch3, DLL3, SNW1, and Jag1 were the genes altered (defined as amplification, upregulation or downregulation of expression, mutation, or homozygous deletion) most frequently (17%, 16%, 15%, and 9% of cases, respectively; Fig. 1A). In total, 61% of the HGS-OvCa cases had alterations of at least one of the Notch pathway–related genes. Patients with these alterations had shorter OS durations than did those without the altered genes (median, 36.2 vs. 53.2 months; P = 0.001; Fig. 1B). The types of alterations for each of the nine genes are shown in Fig. 1C. Notch pathway alterations were not significantly associated with other clinical parameters, including tumor stage (as defined by the International Federation of Gynecology and Obstetrics), grade, and residual tumor size (Supplementary Table S1A and S1C). Mutations of Notch2–4 did not occur frequently in HGS-OvCa cases (Supplementary Table S1B), and there were no alterations in Notch1 or DLL1.

We next focused specifically on Notch3 due to its frequent alterations. Patients with Notch3 alterations had significantly shorter OS durations than did patients without these alterations (median, 35.3 vs. 52.2 months; P = 0.0005; Fig. 2A). Furthermore, patients with amplification, increased expression, and mutation of Notch3 genes had significantly shorter OS durations than did those without these alterations (median OS duration, 33.6 vs. 53.2 months; P = 0.0014; Fig. 2B). Notch3 amplification alone was not associated with OS duration, but there was a trend of shorter OS duration in patients with amplification (Supplementary Fig. S1A). Notch3 expression was correlated with its amplification (P < 0.001; Fig. 2C), according
to Spearman correlation analysis. Notch3 overexpression was also significantly correlated with the GATA2 and C/EBP transcription factors based on Spearman correlation analysis (Supplementary Table S3). Importantly, we identified a significant correlation between Jagged-1 and Notch3 expression in HGS-OvCa samples as well as in breast, uterine, and kidney cancers (Fig. 2D; Supplementary Fig. S1B; Table 1). Notch3 amplification and upregulation were also significantly correlated with shorter survival in patients with uterine cancer (median OS duration, 56 months); patients without these alterations were still alive at the end of this study ($P = 0.0008$; Fig. 2E).

**Biologic effects of Notch3 and cleaved Notch3 in cancer cells**

We first used Western blot analysis to screen a panel of OvCa cell lines for expression of Notch family members (Fig. 3A and B). We selected both cleaved Notch3 (NICD3)-positive (OVCAR3, OVCAR5, and A2780) and NICD3-negative (SKOV3, SKOV3 TR, and IGROV1) OvCa cells for additional *in vitro* and *in vivo* studies. After transfecting cancer cells with Notch3 siRNA (Supplementary Fig. S2A), we noticed high levels of apoptosis in the NICD3-positive cells (Fig. 3C–E), but not in the NICD3-negative cells (Fig. 3F–H); these results suggest that NICD3 expression is an important determinant of the biologic functions of Notch3 in cancer cells. Furthermore, compared with control cells, anoikis increased greatly in NICD3-positive cells transfected with Notch3 siRNA (Supplementary Fig. S2B). Notch3 siRNA also induced cell-cycle arrest in the G2–M phase in NICD3-positive cells, but not in NICD3-negative cells (Supplementary Fig. S2C).

To determine whether the cleaved Notch3 is a determinant of sensitivity to Notch-targeted therapy, we treated human epithelial OvCa cells (OVCAR5, OVCAR3, SKOV3, HeyA8, and A2780) with a GSI at various concentrations for 72 hours and assessed cell viability. The IC$_{50}$ of GSI ranged from 3.06 to 7.73 μmol/L. The NICD3-positive cells (A2780, OVCAR3, and OVCAR5) were more sensitive to treatment with GSI than...
ship between Spearman rank correlation coef-
cleaved Notch3 expression, we next used TCGA data and the
association between the gamma-secretase complex and
native cells (Supplementary Fig. S3). Because there was no
differentially expressed between the NICD3-positive or -neg-
complex in the panel of OvCa cells. These
qRT-PCR to examine the expression of the gamma-secretase
examined whether
APH1B
of the gamma-secretase complex (Fig. S4A). Importantly, dynasore prevented Jagged-1
stimulat-
were the NICD3-negative cells (SKOV3 and HeyA8; Fig. S2D).
GSI-based treatment induced substantially more apoptosis in the
NICD3-positive cells than in the NICD3-negative cells (Supplementary Fig. S2E).

Because Notch3 siRNA arrested cells in the G2–M phase, we
examined whether Notch3 siRNA could enhance sensitivity to paclitaxel. We found that silencing Notch3 significantly enhanced the sensitivity of OVCAR3 cells to treatment with paclitaxel (P < 0.01; Supplementary Fig. S2F–S2G)

**Dynamin-dependent endocytosis is required for Jag1-mediated Notch3 activation**
Next, we considered potential explanations for selective cleaved Notch3 expression in cancer cell lines. Given the role of the gamma-secretase complex (PSEN1, APH1A, NCSTN, APH1B, and PSEN1) in Notch proteolysis, we first used qRT-PCR to examine the expression of the gamma-secretase complex in the panel of OvCa cells. These five genes were not differentially expressed between the NICD3-positive or -negative cells (Supplementary Fig. S3). Because there was no association between the gamma-secretase complex and cleaved Notch3 expression, we next used TCGA data and the Spearman rank correlation coefficient to analyze the relationship between Notch3 and its potential ligands in patients with HGS-OvCa. There was a significant correlation between Notch3 and Jagged-1 expression in HGS-OvCa as well as other cancers, including cancers of the uterus, breast, and kidney (P < 0.0001; Table 1). Therefore, we next evaluated whether Jagged-1 stimulation could induce Notch3 proteolysis in NICD3-nega-
were recombinant human Jagged-1 (rhJagged-1; 10 μg/mL) at 48 hours increased cleaved Notch3 expression in these cells compared with controls (Fig. 4A), Jagged-1 silencing did not decrease cleaved Notch3 levels in NICD3-positive cells (Fig. 4B). These findings prompted us to consider whether endocytosis may be involved in Notch3 activation.

To determine whether endocytosis is involved in Notch3 proteolysis, OVCAR3 cells were treated with dynasore, a cell-permeable inhibitor of dynamin. Cleaved Notch3 expression was decreased in a time- and dose-dependent manner (Fig. 4C and D). Dynasore treatment indeed increased the expression of full Notch3 expression at lower doses and at 1 to 24 hours, likely due to its rapid effect on inhibiting Notch3 receptor degrada-
tion, but this treatment decreased full Notch3 and Jagged-1 at higher doses and 48 hours (Fig. 4C and D and Supplementary Fig. S4A). Importantly, dynasore prevented Jagged-1–stimulated cleaved Notch3 expression in the NICD3-negative cells (SKOV3 cells, HeyA8, and 2774), suggesting that endocytosis was required for Jagged-1–mediated Notch3 activation (Fig. 4E; Supplementary Fig. S4B). Next, to identify which dynamins are involved in this endocytic process to activate Notch3, we screened a panel of OvCa cells for expression of DNM1, DNM2, and DNM3. Among these, DNM1 and DNM2 were expressed in all the cells tested, but DNM3 was present only in some cells (Supplementary Fig. S4C). We then treated the OVCAR3 cells with DNM1, DNM2, or DNM3 siRNA or pools of two or three of these dynamin siRNAs (Supplementary Table S4 and Supplementary Fig. S4D). Treatment with the pools of three dynamin siRNAs resulted in much lower cleaved expression in the OVCAR3 cells than did treatment with the individual siRNA duplexes (Fig. 4F), demonstrating that dynamin-dependent endocytosis was a critical determinant of Notch3 activation.

To determine whether inhibiting dynamin-mediated endocytosis via dynasore could affect apoptosis, NICD3-positive

### Table 1. Correlation between Notch3 and Jagged-1 expression in human cancers

<table>
<thead>
<tr>
<th>Cancer type</th>
<th>Coefficient</th>
<th>P</th>
<th>Sample size</th>
</tr>
</thead>
<tbody>
<tr>
<td>HGS-OvCa (Affymetrix microarray)</td>
<td>0.33</td>
<td>3.28E–16</td>
<td>569</td>
</tr>
<tr>
<td>HGS-OvCa (Agilent microarray)</td>
<td>0.29</td>
<td>3.48E–12</td>
<td>571</td>
</tr>
<tr>
<td>HGS-OvCa (IlluminaRNASeq)</td>
<td>0.46</td>
<td>2.09E–22</td>
<td>411</td>
</tr>
<tr>
<td>HNSC</td>
<td>0.08</td>
<td>0.16677</td>
<td>303</td>
</tr>
<tr>
<td>LGG</td>
<td>0.50</td>
<td>&lt;0.0000001</td>
<td>174</td>
</tr>
<tr>
<td>BRCA-TNBC</td>
<td>0.28</td>
<td>0.002383</td>
<td>112</td>
</tr>
<tr>
<td>BRCA-ER</td>
<td>0.33</td>
<td>4.8E–05</td>
<td>149</td>
</tr>
<tr>
<td>BRCA-ER</td>
<td>0.46</td>
<td>&lt;0.000001</td>
<td>511</td>
</tr>
<tr>
<td>BRCA-PR</td>
<td>0.31</td>
<td>4.65E–06</td>
<td>215</td>
</tr>
<tr>
<td>BRCA-PR</td>
<td>0.51</td>
<td>&lt;0.0000001</td>
<td>443</td>
</tr>
<tr>
<td>BRCA-HER2</td>
<td>0.41</td>
<td>&lt;0.0000001</td>
<td>582</td>
</tr>
<tr>
<td>BRCA-HER2</td>
<td>0.5</td>
<td>4.54E–07</td>
<td>95</td>
</tr>
<tr>
<td>CRC</td>
<td>0.13</td>
<td>0.035451</td>
<td>264</td>
</tr>
<tr>
<td>KIRC</td>
<td>0.73</td>
<td>3.17E–78</td>
<td>470</td>
</tr>
<tr>
<td>UCEC</td>
<td>0.42</td>
<td>0.000001</td>
<td>333</td>
</tr>
<tr>
<td>LUSC</td>
<td>0.37</td>
<td>2.27–08</td>
<td>223</td>
</tr>
</tbody>
</table>

Abbreviations: BRCA, breast invasive carcinoma; CRC, colon and rectum adenocarcinoma; HNCS, head and neck squamous cell carcinoma; LGG, brain low-grade glioma; LUSC, lung squamous cell carcinoma; KIRC, kidney renal clear cell carcinoma; TNBC, triple-negative breast cancer; UCEC, uterine corpus endometrioid carcinoma.
cells (OVCAR5, OVCAR3, and A2780) and NICD3-negative cells (SKOV3) were treated with dynasore (60 \mu\text{mol/L}) for 72 hours. Induction of apoptosis was significantly higher in the Jag1/NICD3-positive cells (A2780 and OVCAR3) than in the Jagged-1/NICD3-negative cells (SKOV3; Fig. 5A; \(P < 0.001\)). Apoptosis was only slightly increased in the NICD3-positive OVCAR5 cells.
treated with dynasore, likely because of the weak expression of Jagged-1 in these cells (Fig. 5A). Induction of apoptosis by Dynasore treatment was also noted in uterine cancer cells (Ishikawa), which express Notch3 and Jagged-1 (Supplementary Fig. S4E and S4F). Dynasore treatment increased Jagged-1 expression in uterine cancer cells (Supplementary Fig. S4E), which may occur due to a possible feedback loop of Notch inhibition or cross-talk with other pathways such as Wnt/β-catenin.

Next, we searched for potential Notch3-targeted genes that could be involved in apoptosis in OvCa cells by hierarchical clustering analysis following Notch3 silencing. There were 461 genes differentially expressed in the OVCAR3 cells following Notch3 silencing, when defined as a fold change > 0.7 (Supplementary Table S4). Given the robust induction of apoptosis in NICD3-positive cells, a pathway analysis focusing on apoptosis was performed. Among the 56 genes in this pathway, \textit{RPS6KB1} expression was particularly downregulated in response to Notch3 silencing (Fig. 5B). Moreover, dynasore treatment decreased \textit{RPS6KB1} expression by 3.0- and 1.3-fold in OVCAR3 and A2780 cells, respectively (Fig. 5C); we found that cleaved poly ADP ribose polymerase dramatically increased in OVCAR3 and A2780 cells, but not in SKOV3 cells, suggesting that \textit{RPS6KB1} was a dominant downstream target of the Notch3 pathway involved in apoptosis. Because it has been reported that PI3K/AKT/mTOR signaling could be modulated by direct repression of PTEN via the Notch target gene \textit{Hes1} or \textit{cMyc} (12), we tested \textit{cMyc} and \textit{HES1} in these cells following dynasore treatment. Dynasore treatment decreased \textit{cMyc} and \textit{HES1} levels by 2-fold in the OVCAR3 and A2780 cells, but not in the NICD3-negative cells (Fig. 5C and D).

We also validated the target modulation \textit{in vivo} by examining the effects of Dynasore on expression of Jagged-1, cleaved Notch3, HES1, and \textit{RPS6KB1} in the A2780 model. After two i.p.

---

**Figure 4.** Notch3 activation by dynamin (DNM)-dependent endocytosis. A, effect of Jagged-1 stimulation on Notch3 activation in SKOV3 cells. B, effect of Jagged-1 silencing on Notch3 activation in OVCAR3 cells. C and D, effect of treatment with dynasore on Notch3 activation in OVCAR3 cells at different time points and doses. E, effect of treatment with dynasore on Jagged-1–mediated Notch3 activation in NICD3-negative ovarian cancer cells (SKOV3, 2774, and HeyA8). F, effect of dynamin silencing on Notch3 activation in OVCAR3 cells.
Figure 5. Microarray analysis of Notch3-targeted genes in ovarian cancer cells. A, analysis of apoptosis in NICD3-positive and NICD3-negative cells after exposure to dynasore for 72 hours. *, \( P < 0.05; \) **, \( P < 0.01. \) B, pathway analysis of apoptosis-related genes in OVCAR3 cells treated with Notch3 siRNA or control siRNA. C and D, Western blot and image analysis of RPS6KB1, cleaved PARP, cMyc, and Hes-1 in ovarian cancer cells treated with dynasore. E, Western blot analysis of target modulation (cleaved Notch 3, HES1, Jagged-1, and RPS6KB1) in tumor tissues obtained from the in vivo A2780 model. Ovarian cancer cells were injected intraperitoneally into the mice. Three weeks later, the mice were randomly allocated to two treatment groups (\( n = 5/g\)group): (i) control, (ii) dynasore.
injections of dynasore (60 mg/kg), cleaved Notch3, HES1, and RP6SKB1 levels, but not Jagged-1, were decreased in tumors treated with Dynasore (Fig. 5E).

**In vivo targeting of Notch3 with siRNAs**

On the basis of our in vitro findings, we next tested whether silencing Notch3 could induce apoptosis in vivo and enhance sensitivity of cancer cells to chemotherapy. For in vivo testing, the A2780 (NICD3/Jagged-1–positive) and SKOV3 (NICD3/Jagged-1–negative) models were used. For systemic delivery of siRNA, the well-characterized CH delivery system (8) was used. In the A2780 model, tumors treated with Notch3 siRNA-CH or paclitaxel alone weighed 74.1% (P = 0.0093) and 75.7% (P = 0.0081) less, respectively, than control siRNA-CH–treated tumors (Fig. 6A). Combining Notch3 siRNA-CH and paclitaxel reduced tumor weight by 99.3% (P = 0.003, compared with tumor weight in control mice). Mice receiving this combination treatment also had significantly fewer tumor nodules on average than did control siRNA-CH–treated mice (P = 0.001).

In the SKOV3 model, Notch3 silencing did not affect tumor weight or the number of tumor nodules (Fig. 6B). Treatment with Notch3 siRNA-CH did not significantly affect body weight (Supplementary Fig. S5A). In the OVCAR5 (NICD3-positive) model, tumors treated with Notch3 siRNA-CH or paclitaxel alone weighed 49.1% (P = 0.0432) and 60.7% (P = 0.013) less, respectively, than did the control siRNA-CH tumors (Fig. 6C). Also, combining Notch3 siRNA-CH and paclitaxel decreased tumor weights by 78.7% and 72.3%, respectively, from weights...
with either treatment alone ($P = 0.001$ and 0.003, respectively). Body weight was not significantly affected by treatment (Supplementary Fig. S5A).

Notch3 levels were significantly decreased in the Notch3 siRNA-CH-treated groups compared with the levels in the untreated mice ($P < 0.01$). In the A2780 model, apoptosis was significantly higher in the tumors treated with Notch3 silencing than in untreated cells (Fig. 6D–G, $P < 0.01$). Compared with the controls, proliferation and angiogenesis were significantly decreased in the tumors treated with the combination therapy. Similar effects were noted in the OVCAR5 model ($P < 0.01$; Supplementary Fig. S5B–S5E).

Discussion

The key findings from our work are that Notch pathway alterations are prevalent and significantly related to poor clinical outcome in patients with ovarian cancer. Particularly, Notch3 alterations, including amplification and upregulation, were highly associated with poor survival. Targeting Notch3 inhibited the growth of ovarian cancer and induced apoptosis. Importantly, we found that dynamin-mediated endocytosis was required for selectively activating Jag1-mediated Notch3 signaling. Cleaved Notch3 expression was the critical determinant of response to Notch-targeted therapy. Collectively, these data identify previously unknown mechanisms underlying Notch3 signaling and identify new, biomarker-driven approaches for therapy.

Why Notch3 expression is preferentially upregulated in patients with ovarian cancer is not clear. Several mechanisms may contribute to its upregulation. Notch3 upregulation was partially correlated with its amplification; Notch3 expression may be caused by transcriptional activation or loss of negative regulators such as SNAI1, because the ability of NIDCD3 to recruit coactivators and corepressors and undergo conformational changes is different from that of Notch1 and Notch2 (13). However, we cannot rule out a role for SNAI1 in the negative regulation of Notch3 pathway activation in such cases (14). Unlike the proteolysis findings with Notch1, Notch2, and Notch4, we found that Notch3 proteolysis was selectively activated in ovarian cancer cells. We considered potential explanations for selective cleaved Notch3 expression in ovarian cancer cells, such as differential expression of the gamma-secretase complex in NIDCD3-positive and NIDCD3-negative ovarian cancer cells, preferential pairing of ligands and Notch3, and ligand endocytosis for signaling activation and receptor degradation. Our data did not support an association between the gamma-secretase complex and cleaved Notch3 expression in NIDCD3-positive versus -negative ovarian cancer cells. It has been suggested that preferential pairing of Notch3 and Jagged-1 or DLL4 can occur in colon cancer cells (13). We found that Notch3 proteolysis was selectively activated in ovarian cancer cells in a Jagged-1–dependent manner, which highlights a critical role for Jagged-1 in activating Notch3 signaling. Jagged-1 expression has also been reported to be regulated directly by Notch 3 and Wnt/β-catenin in ovarian cancer, which might contribute to maintaining long-term Notch3 signaling activation in cancer cells (15).

The exact function of ligand endocytosis in intracellular signaling is unknown. Two possible models have been reported: one that involves ligand-induced Notch signaling (16–18) and another that involves alternative endocytic adaptors such as dynamin, epsins, and actin (17). Before our work, role of endocytic adaptors in Jagged-1–mediated endocytosis in activating Notch3 in ovarian cancer was unknown. Three different dynamin genes have been identified in mammals, including DNM1, DNM2, and DNM3. Dynamin has been reported as an endocytic adaptor that functions in membrane tabulation and fission of budding vesiculo–tubular structures and regulates ligand internalization (19). We demonstrated that selective Notch3 activation is dependent on dynamin-mediated endocytosis and blocking dynamins with dynamin inhibitor significantly increased apoptosis in ovarian cancer, which represents an innovative strategy for inhibiting Notch3 activation.

Taken together, our findings demonstrate that Notch pathway alterations, especially in Notch3 (amplification or upregulation of expression), are prevalent in HGSC-OvCa cases and shorten OS durations. Cleaved Notch3 is a key determinant of Notch3 biology, and dynamin-mediated endocytosis is required for Jagged-1–mediated Notch3 activation. Targeting Notch3 pathway activation with dynamin inhibitors (20) combined with paclitaxel could be considered for future clinical investigation.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Authors’ Contributions

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): J. Huang, T. Miyake, H.J. Dalton, R. Rupaimoole, H.D. Han, J. Bottsford-Miller, Y. Kang, A.K. Sood
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): W. Hu, J. Huang, J. Liu, S.L. Tucker, G. Lopez-Berestein, A.K. Sood
Study supervision: W. Hu, A.K. Sood
Network Analyses: V. Schgal

Acknowledgments

The authors thank Nicholas B. Jennings for technical support and Diane Hackett and Jill Delsigne, Department of Scientific Publications, for editing the article.

Grant Support

This work was supported in part by the NIH (grants P00 CA083639, CA109298, P50 CA098258, UH2 TR000943, CA128797, R01 CA177909, and U54 CA151668), the Ovarian Cancer Research Fund (a Program Project Development Grant), the United States Department of Defense (grants OC120547 and OC993146), the Zarrow Foundation, the Marcus Foundation, the Chapman Foundation, the Meyer and Ida Gordon Foundation #2, the Betty Anne Ashe Murray Distinguished Professorship, MD Anderson Cancer Center Support
References


The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received July 19, 2013; revised February 11, 2014; accepted March 18, 2014; published OnlineFirst April 17, 2014.
Notch3 Pathway Alterations in Ovarian Cancer
Wei Hu, Tao Liu, Cristina Ivan, et al.


**Updated version**
Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-13-2066

**Supplementary Material**
Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2014/04/17/0008-5472.CAN-13-2066.DC1

**Cited articles**
This article cites 19 articles, 5 of which you can access for free at:
http://cancerres.aacrjournals.org/content/74/12/3282.full.html#ref-list-1

**Citing articles**
This article has been cited by 2 HighWire-hosted articles. Access the articles at: /content/74/12/3282.full.html#related-urls

**E-mail alerts**
Sign up to receive free email-alerts related to this article or journal.

**Reprints and Subscriptions**
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

**Permissions**
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.